Radioiodine treatment constitutes the most effective therapeutic option of advanced differentiated thyroid cancer. Unfortunately, about 30% cancers do not show radioiodine uptake or do not respond to therapy.

Thyrosine kinase inhibitors (TKI), among them axitinib, cabozantinib, lenvatinib, motesanib, pazopanib, sorafenib, sunitynib and vandetanib, constitute a new group of drugs implemented to therapy of both differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). They inhibit growth factor receptors which play crucial role in processes of growth, differentiation and maturation of neoplastic cell. Detailed information related to mechanism of action of each drug as well as to conducted clinical trials are given in the table below:

  Drug name      Mechanism of action                  Clinical trials (phase)   Indications
  -------------- ------------------------------------ ------------------------- -------------
  MOTESANIB      VEGFR1,2,3, PDGFR, c-KIT, RET        II                        MTC, DTC
  SORAFENIB      B-RAF, VEGFR1, VEGFR2                II/III                    MTC
  AXITINIB       VEGFR, c-KIT, PDGFR-B                II                        DTC
  SUNITINIB      VEGFR1, 2, PDGFR, c-KIT, FLT3, RET   II                        DTC
  LENVATINIB     VEGFR1,2,3, FGFR1 PDGFR              II/III                    MTC
  CABOZANTINIB   MET, VEGFR2, RET                     III                       DTC
  PAZOPANIB      VEGFR, PDGFR, c-KIT                  II                        MTC
  VANDETANIB     RET, VEGFR, VEGFR2, EGFR             II                        DTC

Until now the only registered drug in advanced MTC is vandetanib. Its efficacy has been proved in phase III study. Significant prolongation of progression free survival (PFS) was observed for patients receiving vandetanib compared with placebo group (30.5 months *vs*. 19 months, respectively). Published results of phase II studies have preliminarily proved the efficacy of axitinib, sorafenib and sunitinib in DTC (beneficial therapeutic effects of partial regression or disease stabilization was noticed in 68%, 76% and 75% cases, respectively). The highest response rate (partial regression) was obtained in DTC patients treated with pazopanib (49%). Whereas, in phase II clinical trials with cabozantynib, motesanib and sorafenib carried out in MTC, disease control was achieved in 90%, 83% and 94% patients, respectively.

The most common side effects are skin reactions such as photosensitivity, rash, hand-food syndrome, arterial hypertension, gastrointestinal -- diarrhea, nausea, vomiting, stomatitis and decrease in body weight. Majority of them have slight or moderate intensiveness (G1 and G2 according to Common Terminology Criteria for Adverse Events). The tolerability of TKI is acceptable and does not affect the quality of life.
